We are analyzing https://link.springer.com/article/10.1007/s00262-017-1954-6.

Title:
PD-1 and PD-L1 antibodies in cancer: current status and future directions | Cancer Immunology, Immunotherapy
Description:
Immunotherapy has moved to the center stage of cancer treatment with the recent success of trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a checkpoint molecule on T cells that plays a vital role in limiting adaptive immune responses and preventing autoimmune and auto-inflammatory reactivity in the normal host. In cancer patients, PD-1 expression is very high on T cells in the tumor microenvironment, and PD-L1, its primary ligand, is variably expressed on tumor cells and antigen-presenting cells within tumors, providing a potent inhibitory influence within the tumor microenvironment. While PD-L1 expression on tumors is often regarded as a negative prognostic factor, it is clearly associated with a positive outcome for treatment with PD-1/PD-L1 blocking antibodies, and has been used to select patients for this therapy. Responses of long duration, a minority of patients with atypical responses in which progression may precede tumor shrinkage, and a pattern of autoimmune side effects often seen with this class of drugs characterize therapy with PD-1/PD-L1 blocking drugs. While excellent efficacy has been seen with a limited number of tumor types, most epithelial cancers do not show responses of long duration with these agents. In the current review, we will briefly summarize the scientific background data supporting the development of PD-1/PD-L1 blockade, and then describe the track record of these antibodies in multiple different histologies ranging from melanoma and lung cancer to less common tumor types as well as discuss biomarkers that may assist in patient selection.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pubmed, article, google, scholar, cancer, cas, central, melanoma, patients, oncol, advanced, nivolumab, chen, tumor, clin, phase, med, hodi, pdl, cell, weber, treatment, blockade, engl, doinejmoa, annual, meeting, death, cells, trial, wolchok, immune, asco, carcinoma, safety, doijco, mcdermott, robert, hamid, urothelial, expression, lung, dois, versus, ipilimumab, metastatic, analysis, programmed, response, horak,

Topics {✒️}

single-agent anti-programmed death-1 month download article/chapter b7-h1/programmed death-1 interactions t-cell-inflamed tumor microenvironment pd-1/pd-l1 blocking drugs anti-pd-1/pd-l1 therapy anti-programmed-death-receptor-1 treatment pd-1/pd-l1 axis blockade pd-1/pd-l1 blocking antibodies anti-pd-l1 antibody mpdl3280a facilitates anti-pd-l1 efficacy article cancer immunology b7-h1/cd80 interaction platinum-based doublet chemotherapy itim motif-carrying immunoreceptor small-cell lung cancer immune-related response criteria immune checkpoint inhibitors pd-l1 diagnostic assays triple-negative breast cancer aacr annual meeting bristol myers squibb advanced renal-cell carcinoma intratumoral t-cell receptor pten promotes resistance tumor antigen-specific cd8 tumor antigen-specific cd8+ full article pdf pd-1/pd-l1 blockade peripheral t-cell tolerance programmed cell death randomised dose-comparison cohort b7-h1 pathway anti-pd-1 therapy cisplatin-based chemotherapy programmed death-1 blockade metastatic urothelial carcinoma adaptive resistance mechanism melanoma tumor microenvironment long-term survival data anti-pd-1 antibody drugs characterize therapy methotrexate/carboplatin/vinblastine mismatch-repair deficiency metastatic urothelial cancer anti-pd-l1 article balar privacy choices/manage cookies immune checkpoint blockade pd-l1-specific

Schema {🗺️}

WebPage:
      mainEntity:
         headline:PD-1 and PD-L1 antibodies in cancer: current status and future directions
         description:Immunotherapy has moved to the center stage of cancer treatment with the recent success of trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a checkpoint molecule on T cells that plays a vital role in limiting adaptive immune responses and preventing autoimmune and auto-inflammatory reactivity in the normal host. In cancer patients, PD-1 expression is very high on T cells in the tumor microenvironment, and PD-L1, its primary ligand, is variably expressed on tumor cells and antigen-presenting cells within tumors, providing a potent inhibitory influence within the tumor microenvironment. While PD-L1 expression on tumors is often regarded as a negative prognostic factor, it is clearly associated with a positive outcome for treatment with PD-1/PD-L1 blocking antibodies, and has been used to select patients for this therapy. Responses of long duration, a minority of patients with atypical responses in which progression may precede tumor shrinkage, and a pattern of autoimmune side effects often seen with this class of drugs characterize therapy with PD-1/PD-L1 blocking drugs. While excellent efficacy has been seen with a limited number of tumor types, most epithelial cancers do not show responses of long duration with these agents. In the current review, we will briefly summarize the scientific background data supporting the development of PD-1/PD-L1 blockade, and then describe the track record of these antibodies in multiple different histologies ranging from melanoma and lung cancer to less common tumor types as well as discuss biomarkers that may assist in patient selection.
         datePublished:2017-02-17T00:00:00Z
         dateModified:2017-02-17T00:00:00Z
         pageStart:551
         pageEnd:564
         sameAs:https://doi.org/10.1007/s00262-017-1954-6
         keywords:
            PD-1
            PD-L1
            Immunotherapy
            Checkpoint inhibitors
            Biomarkers
            Microbiome
            Oncology
            Immunology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:66
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Arjun Vasant Balar
               affiliation:
                     name:NYU Langone Medical Center
                     address:
                        name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jeffrey S. Weber
               affiliation:
                     name:NYU Langone Medical Center
                     address:
                        name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:PD-1 and PD-L1 antibodies in cancer: current status and future directions
      description:Immunotherapy has moved to the center stage of cancer treatment with the recent success of trials in solid tumors with PD-1/PD-L1 axis blockade. Programmed death-1 or PD-1 is a checkpoint molecule on T cells that plays a vital role in limiting adaptive immune responses and preventing autoimmune and auto-inflammatory reactivity in the normal host. In cancer patients, PD-1 expression is very high on T cells in the tumor microenvironment, and PD-L1, its primary ligand, is variably expressed on tumor cells and antigen-presenting cells within tumors, providing a potent inhibitory influence within the tumor microenvironment. While PD-L1 expression on tumors is often regarded as a negative prognostic factor, it is clearly associated with a positive outcome for treatment with PD-1/PD-L1 blocking antibodies, and has been used to select patients for this therapy. Responses of long duration, a minority of patients with atypical responses in which progression may precede tumor shrinkage, and a pattern of autoimmune side effects often seen with this class of drugs characterize therapy with PD-1/PD-L1 blocking drugs. While excellent efficacy has been seen with a limited number of tumor types, most epithelial cancers do not show responses of long duration with these agents. In the current review, we will briefly summarize the scientific background data supporting the development of PD-1/PD-L1 blockade, and then describe the track record of these antibodies in multiple different histologies ranging from melanoma and lung cancer to less common tumor types as well as discuss biomarkers that may assist in patient selection.
      datePublished:2017-02-17T00:00:00Z
      dateModified:2017-02-17T00:00:00Z
      pageStart:551
      pageEnd:564
      sameAs:https://doi.org/10.1007/s00262-017-1954-6
      keywords:
         PD-1
         PD-L1
         Immunotherapy
         Checkpoint inhibitors
         Biomarkers
         Microbiome
         Oncology
         Immunology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:66
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Arjun Vasant Balar
            affiliation:
                  name:NYU Langone Medical Center
                  address:
                     name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jeffrey S. Weber
            affiliation:
                  name:NYU Langone Medical Center
                  address:
                     name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:66
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:NYU Langone Medical Center
      address:
         name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
         type:PostalAddress
      name:NYU Langone Medical Center
      address:
         name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Arjun Vasant Balar
      affiliation:
            name:NYU Langone Medical Center
            address:
               name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
               type:PostalAddress
            type:Organization
      name:Jeffrey S. Weber
      affiliation:
            name:NYU Langone Medical Center
            address:
               name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
      name:Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(353)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.52s.

LINK . SPRINGER . COM {}